RESECTISOL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RESECTISOL (RESECTISOL).
Acetic acid acts as a sclerosing agent by inducing protein denaturation and inflammatory response, leading to fibrosis and obliteration of vascular channels. It also has antimicrobial properties by disrupting cell membranes.
| Metabolism | Metabolized via hepatic oxidation to carbon dioxide and water; acetic acid is rapidly cleared from plasma. |
| Excretion | Primarily renal excretion of unchanged drug (≥90%); <5% fecal. |
| Half-life | 30–45 min; prolonged to 2–4 hours in hepatic impairment or with concurrent halothane. |
| Protein binding | ~85–90%, primarily to albumin and α1-acid glycoprotein. |
| Volume of Distribution | 1.5–2.5 L/kg; high Vd indicates extensive tissue distribution, including brain and adipose tissue. |
| Bioavailability | IV: 100%; IM: ~100% (rapid absorption). |
| Onset of Action | IV: 30–60 seconds; IM: 3–5 minutes. |
| Duration of Action | IV: 5–10 minutes (loss of consciousness); IM: 10–20 minutes. Duration increases with repeated doses due to redistribution. |
Adults: 1–2 mL/kg intravenously once daily.
| Dosage form | SOLUTION |
| Renal impairment | No adjustment recommended; drug is not renally cleared. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated. |
| Pediatric use | 1.5 mg/kg intravenously once daily; maximum 100 mg. |
| Geriatric use | No specific adjustment; monitor renal function due to age-related decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RESECTISOL (RESECTISOL).
| Breastfeeding | Systemic absorption of Resectisol is minimal; excretion into breast milk is unlikely. No studies available; manufacturer recommends caution in nursing mothers. M/P ratio not determined. |
| Teratogenic Risk | Resectisol (sorbitol) is generally not absorbed systemically when used as an irrigation solution, but if significant systemic absorption occurs, it can cause hyperosmolarity and electrolyte disturbances. No specific teratogenic data exist; based on animal studies, no fetal harm is expected at therapeutic doses. However, avoid in pregnancy unless clearly needed. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to acetic acid or any component of the formulation","Active bleeding esophageal varices (except for emergency use)","Severe coagulopathy or thrombocytopenia","Perforated viscus or suspected bowel necrosis","Use in patients with known or suspected portal hypertension-related complications (relative)"]
| Precautions | ["Risk of anaphylaxis or severe allergic reactions","Risk of tissue necrosis if extravasation occurs","Cardiopulmonary effects including arrhythmias and cardiac arrest, especially during esophageal variceal sclerotherapy","Injection site pain, ulceration, and thrombosis","Monitor for signs of infection or bleeding post-procedure"] |
Loading safety data…
| Fetal Monitoring |
| Monitor serum electrolytes, osmolarity, and renal function during prolonged use. Assess fluid balance and signs of volume overload or electrolyte disturbances in both mother and fetus. If systemic absorption suspected, monitor fetal heart rate and uterine activity. |
| Fertility Effects | No known effects on fertility. Resectisol is non-hormonal and has no known impact on reproductive tissues. |